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ABSTRACT
Membrane protein claudin3 has been recently suggested as a marker for 
biologically aggressive tumors and a possible target for the therapeutic delivery of 
active anti-cancer compounds. Claudin3-binding molecules such as the Clostridium 
perfringens enterotoxin (CPE), CPE-related molecules, and murine and chimeric 
antibodies have shown promising antitumor efficacy in preclinical oncological settings. 
We first engineered a fully human anti-claudin3 IgG1 antibody (IgGH6) by fusing 
the human IgG1 Fc-domain to the anti-claudin3 scFvH6 previously isolated from 
a pre-immune phage display library. The construct was expressed in mammalian 
cells and specifically targeted claudin3 endogenously expressed on the surface of 
different human ovarian cancer cell lines. No detectable cross-reactivity with other 
homologous claudins was observed. The epitope recognized by IgGH6 is located 
within the minor extracellular domain of claudin3 and becomes accessible only in 
tumor cells characterized by incomplete junction formation. Confocal microscopy 
experiments demonstrated that IgGH6 was actively internalized in tumor cells after 
binding to native claudin3 and co-localized, likely within intracellular vesicles, with 
the C-CPE peptide. Preliminary results indicate that IgGH6 accumulated in vivo in free 
claudin3 ovarian carcinoma xenografts. For its selective uptake in tumor cells and its 
human nature, IgGH6 represents a valuable candidate for antibody-drug conjugate 
therapeutic applications in ovarian cancer patients.
INTRODUCTION
Claudins form a family of 24 transmembrane 
proteins that are major constituents of tight junction (TJ) 
complexes located at the apical end of the lateral surface 
of polarized epithelia. Although it is well established 
that claudin expression or subcellular localization is 
deregulated in a variety of human malignances [1, 2], 
the role of claudin in cancer progression has not been 
completely elucidated and seems to differ in human 
tumors of different origin. For example, the up-regulation 
of claudin3 and 4 correlates with the progression of 
endometrial carcinoma [3], while the reduced expression 
of claudin1 with poor survival in stage II of colon cancer 
[4]. Furthermore, claudin4 overexpression inversely 
correlated with the metastatic potential of pancreatic 
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cancer cells but positively with the invasiveness of ovarian 
carcinoma cells [5–6].
Loss of TJ integrity leads to cell polarity impairment 
and increased influx of growth factors, a condition 
suspected to favor tumor cells survival and motility [6, 7]. 
In particular, claudin3 basal expression is low in normal 
epithelial cells, but the protein accumulates at the cell 
surface of several biologically aggressive human cancers, 
including breast, prostate, pancreatic, and epithelial 
ovarian tumors [8, 9]. The loss of cellular polarity and 
cell-cell interaction which occurs in cells during neoplastic 
transformation leads to the exposure of TJ components 
on the cell surface, making claudin3 accessible to 
extracellular antibody binding (“free” claudin3) [10]. Due 
to its differential overexpression and accessibility in a 
variety of human tumors, claudin3 might represent both 
a diagnostic biomarker and a potential therapeutic target 
for drug delivery.
Over the years, molecules that specifically recognize 
the extracellular domain of claudins have been identified 
and characterized. In oncological settings, the Clostridium 
perfringens enterotoxin (CPE) and the CPE-related 
peptides have been recently validated in vitro and in 
animal models of human cancer [11] as tumor inhibitors. 
CPE specifically targets the minor extracellular domain 
(ECL2) of claudin3 and claudin4 and strongly inhibits 
uterine and ovarian serous carcinoma cell growth [12]. 
Accordingly, Cocco et al. recently described the use of 
the CPE peptide as a potential carrier for the delivery 
of anti-tumor drugs and as an imaging agent in ovarian 
carcinomas [13]. Unfortunately, the non-human origin 
of CPE and its significant toxicity when administered 
systemically as full length protein will limit its use to local 
treatments [11–14].
Antibodies represent a valuable treatment option 
for the specific targeting of claudin overexpressing 
malignancies. A murine-human chimeric mAb against the 
large extracellular domain of claudin4 [15] and a chimeric 
dual-targeting mAb against claudin3 and claudin4 [16] 
have been recently developed and evaluated for their 
antitumor activity. These reagents demonstrated a dose-
dependent ADCC on pancreatic and ovarian cancer cells 
supporting the anti-cancer therapeutic potential of anti-
claudin antibodies. Also antibody-drug conjugates (ADC), 
with over 30 ADCs currently in clinical development, are 
valuable tools for cancer therapy. FDA approved recently 
two products, the CD30-targeting ADC brentuximab-
vedotin for the treatment of relapsed Hodgkin lymphoma 
and of anaplastic large cell lymphoma [17], and ado-
trastuzumab emtansine (T-DM1) for the treatment of 
HER2/neu-positive metastatic endometrial cancer [18].
Because of its selective accumulation in tumor 
cells, free claudin3 can represent an interesting cancer 
biomarker for targeted delivery of toxic drugs such ADCs 
administered systemically. This strategy is difficult to 
implement due to the difficulty to obtain antibodies against 
a specific claudin by classical immunization approaches 
because of the high homology of claudin sequences in 
human and among species. We had already isolated and 
characterized a human single-chain antibody (scFv) from 
the antibody phage display library ETH2-Gold [19], 
identified as scFvH6, which specifically targets the minor 
extracellular domain of claudin3 [20]. In this work we 
have first reconstituted the anti-claudin3 scFvH6 fragment 
into a complete fully human IgGH6 antibody, then 
evaluated the IgGH6 tumor-binding properties in multiple 
in vitro assays on primary ovarian and uterine cancer cell 
lines, and finally demonstrated its capacity to bind in vivo 
to xenograft mouse models of ovarian cancer.
RESULTS
Engineering, production, and validation of anti-
claudin3 human IgGH6
The sequences corresponding to the VH and VL 
regions encoding for the scFvH6 [20] were re-cloned 
separately in the pFUSE-CHIg-hG1 and pFUSE2-CLIg-hk 
eukaryotic expression vectors for reconstituting a full-size 
human antibody (IgGH6). The IgG1 isotype was chosen 
due to its superior in vitro cytotoxicity and proven efficacy 
in clinical trials [21]. IgGH6 was produced in CHO cells 
to obtain antibodies with human-like post-translational 
modifications. Its production was assessed regularly 
after transfection and maximal yields were obtained 
after 6–7 days (data not shown). Following protein A 
affinity chromatography, 40 μg of purified antibody were 
recovered from 250 mL of culture supernatant. The correct 
molecular weight and IgGH6 integrity were endorsed by 
SDS-PAGE performed under reducing and non-reducing 
condition followed by Coomassie blue staining that 
showed that IgGH6 purity was above 95% (Figure 1A). 
The generation of full-size antibody was confirmed by 
Western Blot analysis that identified the two bands of 
50 kDa and 28 kDa correspondent to the IgG H and L 
chains (Figure 1B). The binding capacity of the engineered 
IgGH6 construct towards its antigen was confirmed by 
surface plasmon resonance measurements. Since claudin3 
is expressed at high density at the surface of ovarian tumor 
cells, we preferred measuring avidity rather than affinity 
to mimic the in situ actual conditions. Specifically, the 
avidity of the bivalent antibody for the peptide 2CL3 
encompassing the claudin3 minor extracellular domain was 
of 15.3 nmol/L (kon = 1.06 × 10
5 1/Ms; koff = 1.62 × 10
−3 1/s, 
Supplementary Figure 1).
The specificity of IgGH6 for claudin3 was evaluated 
by ELISA using the peptides corresponding to the 
conserved minor extracellular domains of claudin3, 4, 
and 7 (Table 1). As shown in Figure 2, IgGH6 retained 
the target specificity encoded by the original scFvH6 and 
exhibited high selectivity towards the desired antigen with 
negligible cross-reactivity to homologous claudins [22].
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Figure 1: IgGH6 expression and purification evaluation. IgGH6 was expressed in CHO cells and isolated by Protein A affinity 
chromatography. A. SDS-PAGE of IgGH6 under non reducing (lane 1) and reducing (lane 2) conditions. B. Western Blot of IgGH6. 
One μg of purified IgGH6 was loaded in lane A and 10 μg of human IgG was loaded as a control in lane B. Molecular weight markers are 
expressed in kDa.
Table 1: Amino acid sequences of the peptides corresponding to the minor extracellular domains 
of claudin3, claudin4, and claudin7
peptide amino acid sequence claudin subtype
2CL3 PVSWSANTIIRDFYNPVVPEAQKREMGAGLY 3
2CL4 TAHNIIQDFYNPLVASGQKREM 4
2CL7 WYGHQIVTDFYNPLIPTNIKYE 7
Figure 2: IgGH6 binds specifically claudin3. Specific binding of scFvH6 and IgGH6 to claudin3 2CL3 peptide compared to their 
binding to peptides 2CL4 and 2CL7 (claudin4 and 7) and to the irrelevant antigen BSA.
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Binding properties on cancer cells
The binding proprieties of IgGH6 on cells were 
evaluated using cancer cell lines expressing variable 
amounts of claudin3. To this aim, different primary ovarian 
and uterine serous carcinoma cells were tested for claudin3 
expression by RT-PCR, FACS analysis and Western 
blotting using commercial rabbit polyclonal antibodies 
against the C-terminus intracellular region of claudin3. 
RT-PCR allowed for the identification of tumor cell lines 
with relative high (OSPC-2), intermediate (USPC-4), and 
low (UCI-107) expression of claudin3 (mean claudin3 
expression was 11.4 folds and 8.1 folds higher in OSPC-2 
and USPC-4 than in UCI-107) (Figure 3A). Western 
blot analysis confirmed at protein level (Figure 3B) that 
claudin3 accumulated in USPC-4 and OSPC-2 cells at 
Figure 3: IgGH6 binding properties on free claudin3 expressing human cancer cell lines. A. Expression of claudin3 mRNA 
in human cancer cell lines USPC-4, OSPC-2, UCI-107 and normal human embryonal kidney HEK293 cells was measured by RT-qPCR 
analysis. Data are shown as the mean ± SE of two independent experiments and are expressed as relative expression ratios (ΔΔCt – Fold 
increase) using HEK293 as a reference. B. 20 ug of cell lysates were separated by SDS-PAGE and probed with anti-claudin3 polyclonal 
antibody. Equal loading was confirmed by incubating the membrane with αTubulin. C. Total claudin3 expression level was evaluated by 
FACS analysis on fixed and permeabilized cells. Single cell suspension were incubated with commercial antibody against claudin3 followed 
by incubation with anti-rabbit-FITC conjugated antibody. Histograms of cells stained with an isotype control antibody (dotted line) or with 
specific anti-claudin3 (solid line) are shown for each cell line tested. The percentage of claudin3 positive cells is reported in each plot. 
D. IgGH6 binding to the extracellular domain of claudin3 was evaluated by FACS analysis on unfixed cells. Single cell suspensions were 
incubated with 2.5 μg/mL of purified IgGH6 for 1 h followed by a 30 min incubation with mouse anti-human IgG-FITC secondary antibody, 
and analyzed by FACS gating on annexin V negative cells. Histograms of cells stained with specific IgGH6 (solid line) or only secondary 
antibody (dotted line) are shown for each of the cell lines tested. The percentage of claudin3 positive cells is reported in each plot.
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higher levels than in UCI-107, whereas no evidence of 
claudin3 presence was observed in TJ-free HEK293 
control cell line. Similar results were obtained by FACS 
analysis using the commercial antibody. Specifically, 
91–98% of USPC-4 and OSPC-2 cells expressed claudin3 
with a MFI of 5.87 and 10.54 on positive cells respectively, 
while only 34% of UCI-107 expressed claudin3 with a MFI 
of 2.43 (Figure 3C). These cell lines were gently detached 
with EDTA to preserve membrane integrity and avoid false 
positivity due to mechanical damage before being used to 
assess the IgGH6 ability to bind the extracellular domain 
of claudin3. Cells were incubated 1 hour with 2.5 μg/mL 
of purified IgGH6 followed by 30 min incubation with 
mouse anti-human IgG-FITC secondary antibody before 
FACS analysis. Cells with damaged membrane labeled 
with Annexin V were excluded from the analysis. 
Figure 3D shows that 47%, 49% and 12% of USPC-2, 
OSPC-4, and UCI-107 cells, respectively, were recognized 
by IgGH6. The mean of fluorescence of USPC-4, OSPC-2 
and UCI-107 was 53, 43 and 16, respectively, consistent 
with the different claudin3 accumulation at the surface 
of these cells. HEK293 cells with no detectable claudin3 
accumulation served as a negative control and did not 
show any significant shift in FACS histogram.
Cellular fate of IgGH6 after binding to claudin3 
on the cell membrane
Immunofluoresence microscopy was used to 
visualize the interaction mechanisms between IgGH6 
and claudin3 on cell membranes. When USPC-4 cells 
were incubated at 4°C to prevent receptor internalization, 
IgGH6 localized at the cell surface, as demonstrated by the 
specific staining that was restricted to foci present along 
the whole cell margins (Figure 4). The pictures clearly 
indicate that the accumulation of claudin3 in OSPC-2 
is not localized in cell-cell contact regions, as typically 
observed for TJ proteins as claudins in healthy tissues, but 
appears also in the upper portion of the cell membrane, 
proving the mislocalization of claudin3 in ovarian tumor 
cells [23].
When cells were incubated 1 hour at 37°C, 
the orthogonal reconstruction of images relative to 
OSPC-2 (Figure 5) and USPC-4 (Supplementary Figure 2) 
reveals intense intracellular fluorescence signal localized 
in spots resembling endosomal vesicles. The carboxy-
terminal fragment (C-CPE290–319 peptide) of Clostridium 
perfringens enterotoxin is known to gradually internalize 
into the cytoplasm of claudin3 and claudin4 positive 
Figure 4: IgGH6 binds claudin3 on USPC-4 cell surface. USPC4 cells were incubated 1 h at 4°C with 2.5 μg/mL of IgGH6 to 
prevent antibody internalization, then cells were fixed, permeabilized, and incubated with the Alexa594-conjugated secondary antibody 
(red) panel A. Cell membrane and nuclei were stained with WGA-Alexa488 (green) panel B and DAPI (blue), respectively. Images were 
collected using a Zeiss Axiovert 200M epifluorescence microscope equipped with a Plan-Apochromat 63x/1.4 NA oil objective; z-stack 
images were acquired using ApoTome system and elaborated Inside4D module. panel C shows images resulting from merging the three 
different channels. IgGH6 binding at the cell-cell contact (arrowhead) and on the cell surface outside the TJ area (arrow) are visualized.
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ovarian cancer cells after binding to the minor extracellular 
domain of the claudins [13]. We hypothesized a similar 
mechanism for the IgGH6 uptake and, consequently, 
incubated 1 hour at 37°C OSPC-2 cells in the presence 
of both FITC conjugated C-CPE290–319 peptide and 
IgGH6. As shown in Figure 6, the two claudin3 binders 
show a strong co-localization inside the cells suggesting 
that the antibody undergoes the same claudin3-mediate 
internalization process previously described for the C-CPE 
peptide [14].
IgGH6 in vivo specific targeting of free claudin3 
tumors
To assess whether IgGH6 was able to localize to 
free claudin3-overexpressing ovarian cancer in vivo, 
sub-cutaneous OSPC-ARK-1-derived xenografts were 
generated as previously described [24]. Four weeks after 
tumor implantation, 20 μg of IgGH6 labeled with the 
Near InfraRed dye 790-I were injected intravenously and 
6 hours later tumors were excised and visualized using 
an In Vivo FX PRO system. Strong fluorescent signal was 
observed in tumors excised from animals injected with 
IgGH6–790-I, while negligible staining was detected 
in tumors excised from vehicle-injected control mice 
(Figure 7, IR, merge and camera pictures).
DISCUSSION
The possibility of targeting specifically neoplastic 
cells while sparing healthy tissues would significantly 
improve the tollerability of anti-cancer therapies and, 
accordingly, there is an enormous interest in identifying 
biomarkers and reagents suitable for selective drug 
delivery. Claudin3 has recently emerged as a potential 
cancer biomarker as a diagnostic as well as a therapeutic 
target [8, 12] because it is over-expressed selectively in 
several biologically aggressive human tumors. Our group 
has already described the feasibility to target aggressive 
gynecologic cancers with claudin3- and 4-binding 
CPE [13, 25]. The molecular mechanism of the CPE-
claudin3 interaction has been extensively investigated and 
allowed for the identification of the minor extracellular 
domain as the sequence motif involved in the CPE 
binding [26]. Unfortunately, the CPE toxicity prevents its 
systemic administration in human patients, whereas the 
development of novel and nontoxic analogues specific for 
claudin3 would be highly desirable.
Recently, our group isolated a recombinant 
antibody fragment (scFvH6) specific to the ECL2 domain 
of claudin3 using a synthetic human phage display 
library [20]. Given the promising results obtained with 
anti-claudin3 murine and chimeric antibodies used for 
Figure 5: IgGH6 binds and internalizes claudin3 in OSPC-2 cells. OSPC-2 cells were incubated 1 h at 37°C with 2.5 μg/mL 
of IgGH6 to allow antibody internalization, then cells were fixed, permeabilized and incubated with the Alexa594-conjugated secondary 
antibody (red) panel A. Cell membrane and nuclei were stained with WGA-Alexa488 (green) panel B. and DAPI (blue), respectively. 
Images were collected using a Zeiss Axiovert 200M epifluorescence microscope equipped with a Plan-Apochromat 63x/1.4 NA oil 
objective; z-stack images were acquired using ApoTome system and elaborated Inside4D module. panel C. shows images resulting from 
merging the three different channels.
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Figure 6: IgGH6 internalizes with CPE290–319 peptide. OSPC-2 cells were incubated 1 h at 37°C with 2.5 μg/mL of IgGH6 in 
the presence of [10 μg/mL] FITC-CPE290–319 peptide (green) panel A to allow antibody and peptide internalization, then cells were fixed, 
permeabilized and incubated with the Alexa594-conjugated secondary antibody (red) panel B. Nuclei were stained with DAPI (blue). 
Images were collected using a Zeiss Axiovert 200M epifluorescence microscope equipped with a Plan-Apochromat 63x/1.4 NA oil 
objective; z-stack images were acquired using ApoTome system and elaborated Inside4D module. panel C shows images resulting from 
merging the three different channels, with arrows showing IgGH6 and CPE peptide colocalization in the cell cytoplasm.
Figure 7: IgGH6–790-I tumor binding capacity in vivo. OSPC-ARK-1-derived xenografts were injected IV with 20 μg of IgGH6–
790-I. After 6 hours, mice were sacrificed and tumors were excised and visualized using an In-Vivo FX PRO system (Bruker Corporation, 
Billerica, MA; excitation/emission 760/830 nm; exposure time 60 seconds). Strong fluorescence was observed in tumors excised from 
IgGH6–790-I injected animals while negligible staining was detected in tumors excised from mice injected with the vehicle (PBS).
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ADCC [15, 16], we developed a full human functional 
IgG reagent (IgGH6) starting from the original scFvH6 
fragment molecule that conserved the original selective 
binding characteristics for the claudin3 expressed at the 
surface of ovarian cancer cells.
Extracellular domains of claudins are involved in 
the formation of TJ, in which they interact in homotypic 
and heterotypic manner [27]. Whereas in normal 
confluent epithelial cell monolayer claudin3 is expected 
to localize within the TJ strand at the apical site of the 
lateral membrane, the known dis-regulation of the mitotic 
spindles during epithelial tumorigenesis and the resulting 
out-of-plane division in tumor cells was suspected to 
induce abnormal localization of TJ components at the cell 
surface [28]. However, the detection of “free” claudins, 
and specifically of claudin3, in such tumor cells has 
been difficult to assess in the past because of the lack of 
commercially available antibodies specific for claudin 
extracellular domains. In the present study, the IgGH6-
immunofluorescence of USPC-4 and OSPC-2 cancer 
cell lines clearly demonstrated scattered focal claudin3 
expression along the whole cell membrane, instead of 
the physiological distribution pattern of healthy cells in 
which the protein is strictly localized at TJ. Our results 
are in agreement with those of Winkler et al. [26] who 
demonstrated that CPE binds to the free domain of claudin3 
that is not occupied by trans-interaction with homologous 
claudins and is not incorporated in TJ strands. Summarizing, 
the collected data underline two issues that are critical for 
the therapeutic potential of IgGH6: i) in cancer cell lines 
this fully human antibody reacted exclusively with claudin3 
not engaged in forming TJ; ii) this form of free claudin is a 
specific biomarker for ovarian cancer cells.
In principle, the focal expression of the target 
antigen on cancer cell surface may diminish the anti-
tumor efficacy of an antibody designed for ADCC therapy 
because of the limited number of targetable molecules. 
However, the very specific accumulation of the IgGH6-
targetable, accessible free claudin3 only in cancer cells 
and its absence in healthy, polarized epithelial cells 
would represent ultimately a major advantage for ADC 
[29] because selectivity for the tumor cells and minimal 
toxicity are the most relevant requisites for this therapeutic 
approach. Also the confocal microscopy experiments 
that demonstrated the fast and effective internalization 
of IgGH6 in OSPC-2 and USPC-4 cells favor the use of 
this antibody for ADC [30, 31] rather than for ADCC that 
requires the stable binding of the antibody to the external 
surface of the target cells. Remarkably we have also shown 
that IgGH6 accumulates in vivo in xenograft models of free 
claudin3-expressing ovarian cancer following systemic 
administration. Tumor explanted 6 hrs after IgGH6–790-I 
injection was strongly fluorescent, while untreated tumor 
tissues did not show any detectable signal.
In contrast to the already available anti-claudin 
murine and chimeric antibodies [15, 16], the human nature 
of IgGH6 would minimize immune reactions that could 
prevent the treatment iteration. To our knowledge, this is the 
first human antibody which specifically targets the minor 
extracellular domain of the tumor-associated claudin3.
Now that the binding and interalization kinetics 
of IgGH6 have been thorughly characterized, we plan 
its fusion to active toxins and the in vivo experiments 
necessary to identify the optimal treatment conditions and 
to validate the therapeutic potential of IgGH6-based ADC 
reagents to use against claudin3-expressing malignancies.
MATERIALS AND METHODS
Cancer cell lines and cell culture
Primary ovarian serous carcinoma cell line 
OSPC-2 and chemotherapy-resistant primary ovarian 
serous papillary carcinoma cell line OSPC-ARK1 
were established from samples obtained, respectively, 
at the time of primary surgery or collected at the time 
of tumor recurrence from a patient harboring stage 
IV OSPC. Primary uterine serous carcinoma cell line 
USPC-4 was established from samples collected at 
the time of tumor recurrence from an intra-abdominal 
metastatic site. Primary cell lines and ovarian carcinoma 
cell line UCI-107 were maintained at 37°C in 5% CO2 
in RPMI-1640 medium supplemented with 10% FBS. 
HEK293 cells, free of endogenous claudins and of 
TJ strands [32] were evaluated as a negative control. 
HEK293 were cultured in DMEM (Dulbecco’s modified 
Eagle’s medium) supplemented with 10% FBS. Chinese 
hamster ovary (CHO) cells, cultured in suspension 
(1 × 105 cells/mL) in CD-CHO medium (GIBCO, Life 
Technologies) supplemented with L-Glutamine 8 mM and 
HT Supplement, were incubated at 37°C in a humidified 
atmosphere of 5% CO2 on an orbital shaker platform.
Quantification of claudin3 mRNA by 
real-time PCR
Total RNA was extracted with Trizol reagent 
(Life Technologies) and treated with TURBO DNase 
enzyme (Ambion, Applied Biosystems) to remove the 
contaminating DNA eventually present. First-strand cDNA 
was synthesized using SuperScript II reverse transcriptase 
(Life Technologies) and q-PCR performed with an 
ABI Prism 7000 Sequence Analyzer according to the 
manufacturer’s instructions (Applied Biosystems). 25 ng 
of cDNA were amplified by using the TaqMan Universal 
PCR Master Mix (Applied Biosystems). The comparative 
threshold cycle (Ct) method was used to determine gene 
expression in each sample relative to the value observed 
in HEK293 cells. The mRNA expression levels of target 
genes were normalized to the levels of GAPDH transcript. 
The primers for claudin3 were obtained from Applied 
Biosystems as Assay-on-Demand products. Assay ID 
were Hs00265816_s1 (claudin3) and Hs99999905_m1 
(GAPDH).
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Cloning of IgGH6 into eukaryotic expression 
vector and transfection in CHO cells
The VH region encoding scFvH6 was PCR-
amplified using the reverse primer H6-VH-Rev 
(GCTAGCACTCGAGACGGTGACCAGGGTTCC, 
corresponding to downstream VH sequence, with 
the underlined internal NheI restriction enzyme 
site) and the forward primer IL2-H6-VH-Fw 
(CTCGAGatgtacaggatgcaactcctgtcttgcattgcactaagtcttgcac 
ttgtcacgaattcgGAGGTGCAGCTGTTGGAGTCT), con-
taining the IL2 signal peptide sequence (lowercase) in 
frame with the upstream VH sequence (uppercase) and 
an internal XhoI restriction enzyme site (underlined). The 
PCR product was digested with NheI and XhoI before 
being inserted into the expression vector pFUSE-CHIg-
hG1 (InvivoGen), featuring the constant region of the 
human IgG1 heavy chain, predigested with the same 
enzymes.
The VL scFvH6 domain was PCR amplified using 
the reverse primer H6-VL-Rev (CGTACGTTTGATTT 
CCACCTTGGTCCCTTG, corresponding to downstream 
VL sequence, with the underlined internal BsiWI restriction 
enzyme site) and the forward primer IL2-H6-VL-Fw 
(ACCGGTatgtacaggatgcaactcctgtcttgcattgcactaagtcttg 
cacttgtcacgaattcgGAAATTGTGTTGACGCAGTCT 
containing the IL2 signal peptide sequence (lowercase) 
in frame with the upstream VL sequence (uppercase) 
and an internal AgeI restriction enzyme site (underlined). 
The VL PCR product was digested with BsiWI and AgeI 
and cloned into the expression vector pFUSE2-CLIg-hk 
(InvivoGen), featuring the constant region of the human 
immunoglobulin kappa light chain, predigested with the 
same enzymes. The two final resulting constructs, named 
pFUSE-H6VH and pFUSE-H6VL, were then expressed 
in CHO cells and secreted into the medium as a complete 
IgG. Lipofectamine2000 (Life Technologies) was used to 
transiently transfect 50 μg of pFUSE-H6VH and 50 μg 
of pFUSE-H6VL into 4 x 107 CHO cells re-suspended 
in 30 mL of CD-CHO serum-free medium in a 125 mL 
spinner flask. Cells were cultured at 37°C on an orbital 
shaker with humidified atmosphere containing 5% CO2. 
The medium was collected the third day after cell 
centrifugation, replaced by fresh medium and collected 
again after further 4 days of culture.
Production of human IgGH6
ELISA was used to verify the presence of IgGH6 
in CHO supernatant. Streptavidin-coated plates were 
incubated o/n at 4°C with biotin conjugate-goat-anti-
human IgG γ chain specific (1:10000 in PBS, Sigma 
Chemical Company). After blocking, 100μL of IgG-
containing supernatant were added to each well and 
incubated for 1.5 h at RT. Bound IgGs were coupled to 
mouse-anti-human IgG κ chain specific (Santa Cruz, 
1:500 in 1% milk/PBS) and anti-mouse HRP-conjugated 
antibody (Sigma Chemical Company). Color reaction 
was performed in the presence of soluble BM blue POD 
substrate (Roche Diagnostics) and was stopped by the 
addition of 1 M sulfuric acid before plate reading at 
450nm. IgGH6 was purified from CHO supernatants 
using Protein A. Briefly, supernantant was loaded onto 
a 1-mL Protein A Sepharose Fast Flow resin packed in 
a chromatography column (BioRad Laboratories). The 
column was extensively washed with 20 mM sodium 
phosphate buffer, pH 9. Bound antibodies were eluted 
with 0.1 M citric acid, neutralized with 100 mM Tris-HCl, 
pH9, and concentrated on Amicon-Ultra 10K cartridges 
(Amicon). Protein A-purified IgGH6 fractions were 
separated by SDS-PAGE and visualized by Coomassie 
blue staining. IgGH6 heavy and light chains were 
simultaneously detected in a Western Blot assay with a 
biotin-conjugated polyclonal antibody against human 
IgG (Jackson ImmunoResearch Laboratories) coupled 
with HRP-conjugated streptavidin, and immunoreactions 
developed by a chemiluminescent substrate (ECL; 
Amersham Biosciences Corp.).
ELISA binding assay
The 31 amino acid peptide corresponds to the 
second extracellular loop of claudin3 (2CL3) according to 
the predictive model of claudin3 [33] and was previously 
used for the scFvH6 isolation from a pre-immune library 
[20]. The same peptide was used in combination with the 
two peptides 2CL4 and 2CL7 corresponding to the second 
extracellular domain of claudin4 and claudin7 (Table 1) 
to test the IgGH6binding specificity by ELISA. In vitro 
peptide synthesis and N-biotinylation was performed at 
Alpha Diagnostics International. The peptides (100 ng/
well) were absorbed on a streptavidin-coated 96 well plate 
overnight at 4°C. After blocking (5% milk), 100 μL of 
IgGH6-containing supernatant or 400 ng/well of ScFvH6 
were added and incubated for 1 h at RT. Bound IgGH6 
was detected with goat anti-human Fc HRP-conjugated 
antibody (1:10.000; Sigma Chemical Company). Bound 
ScFvH6 was detected with an anti-myc tag antibody (9E10 
clone,1:1500; Roche Diagnostics), followed by anti-mouse 
HRP-conjugated antibody (Sigma Chemical Company) 
as previously described [20]. The immunoreactions was 
developed with soluble BM blue POD substrate (Roche 
Diagnostics), stopped by the addition of 1 M sulfuric acid 
before plate reading at 450nm.
Surface plasmon resonance assay
SPR measurements were performed on a BIAcore 
X instrument (GE-Healthcare Life Science). Biotinylated 
2CL3 peptide (2 μg/mL in 10 mM HEPES, pH 7.4, 
150 mM NaCl, 3 mM EDTA, 0.005% surfactant P20) 
was coated onto the SA streptavidin sensor chip at an 
immobilization density of 1,612 resonance units (RU) 
equal to 0.35 pmol/mm2 of the peptide. Increasing 
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concentrations of IgGH6 in the same buffer buffer were 
injected 4 min before dissociation measurement (10 min). 
After every run, the sensor chip was regenerated by the 
injection of 10 mM glycine, pH 2.0.
Flow cytometry
Total claudin3 expression was evaluated on 
permeabilized cells with rabbit anti-claudin3 polyclonal 
antibody (Life Technologies), followed by incubation with 
anti-rabbit-FITC secondary antibody. The ability of IgGH6 
to recognize cell surface claudin3 was tested on unfixed 
OSPC-2, USPC-4, UCI-107, and HEK293 cells. After 
detachment with 0.5 mM EDTA, cells were incubated for 
1 h with 2.5 μg/mL of purified IgGH6 followed by a 30 min 
incubation with mouse anti-human IgG-FITC secondary 
antibody (Southern Biotech). Cells were acquired on a 
FACS-Calibur flow cytometer and samples were analyzed 
by Cell quest Pro Software (Becton Dickinson) gating on 
Annexin V (BD Pharmingen) negative cells. Percentages 
and mean fluorescence intensity (MFI) of positive cells 
were determined considering the position of hystograms of 
unstained cells and subtracting MFI values of their natural 
fluorescence, respectively.
Immunofluorescence staining and  
internalization
OSPC-2, USPC-4 and UCI-107 cells were seeded 
on cell culture slide (SPL Life Science Co), grown to 50 
to 70% confluency and treated with 2.5 μg/mL of IgGH6 
for 1 hour at 4°C or at 37°C in the absence or in the 
presence of FITC-conjugated Clostridium perfringens 
carboxy-terminal fragment CPE290–319 peptide (10 μg/mL). 
After washing, cells were fixed with 4% formaldehyde for 
15 min at RT and incubated with 0.5 μg/mL of anti-human 
IgG-Alexa647-conjugated antibody. Membrane and nuclei 
were stained with WGA-Alexa488 (Life Technologies) 
and DAPI respectively. Finally, cells were washed with 
PBS and mounted in ProLong Gold antifade reagent 
(Life Technologies). Samples were analyzed using an 
epifluorescence microscope Axiovert 200 equipped with a 
63x/1.4 NA Oil Objective and APOTOME.2 system. Serie 
of Z stack fluorescent images were analyzed by INSIDE 
4D and Extended focus modules of Axiovision software 
(CarlZeiss).
IgGH6–790-I generation and in vivo tumor 
binding capacity
The labeling of IgGH6 to the NearInfraRed dye 
790-I was performed using a commercially available 
kit according to the manufacturer’s protocol (Abnova, 
#KA4185). For the in vivo studies, sub-cutaneous OSPC-
ARK-1-derived xenografts were generated as previously 
described [24]. Briefly, C.B-17/SCID female mice 
5–7 weeks old were purchased from Harlan Sprague-
Dawley (Indianapolis, IN) and housed in a pathogen-free 
environment at Yale University. They were given basal 
diet and water ad libitum. All experimental procedures 
were approved by the Institutional Animal Care and Use 
Committee (IACUC). C.B-17/SCID mice were injected 
subcutaneously with 5 × 106 cells derived from OSPC-
ARK-1. Four weeks later, 20 μg of IgGH6–790-I were 
injected IV and 6 hours later animals were sacrificed 
and tumors were excised and visualized using an In-Vivo 
FX PRO system (Bruker Corporation, Billerica, MA; 
excitation/emission 760/830nm; exposure time 60 seconds). 
As controls, tumors excised from mice injected with the 
vehicle solution were visualized using the same protocol.
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